Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
canuomycin
- Development stage
- Phase 1
- Lead developer
- The University of Hong Kong
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
Canuomycin (also known as kynomycin or YB211) is a novel cyclic lipodepsipeptide antibiotic developed by Mudanjiang Youbo Pharmaceutical (a subsidiary of Jiuzhitang) in collaboration with the University of Hong Kong. It is a methylated derivative of daptomycin, specifically modified by methylation at the non-proteinogenic amino acid kynurenine. This modification enhances its calcium-dependent oligomerization efficiency and stability on bacterial membranes, leading to improved membrane permeabilization and depolarization. Canuomycin exhibits potent bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), as well as daptomycin-resistant strains. It is currently in Phase 2 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and skin structure infections (cSSTI).
- Other names
- kynomycin咔喏霉素
Beyond the preview
Go deeper on canuomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on canuomycin.